Trastornos mentales y tratamiento

Elevated L−aminoisobutyric Acid Aids to the Pathophysiology of Treatment−Resistant Schizophrenia and Clozapine Adverse Effects

Abstract

Damian Fukuyama

This study aims to investigate the potential role of enhancing L-Aminoisobutyric Acid (LAIBA) in the pathophysiology of Treatment-Resistant Schizophrenia (TRS) and its effect on the adverse effects of clozapine. TRS is a challenging form of schizophrenia characterized by a lack of response to conventional antipsychotic medications, including clozapine, which is often prescribed as a last resort. Recent evidence suggests that alterations in neurotransmitter systems, including glutamatergic dysfunction, may contribute to TRS. LAIBA, a non-proteinogenic amino acid, has been shown to modulate glutamatergic transmission. In this study, we investigated the effects of LAIBA on TRS and the adverse effects associated with clozapine treatment in an animal model. Our findings suggest that enhancing LAIBA levels may have therapeutic potential in TRS by regulating glutamatergic signaling and ameliorating the adverse effects of clozapine. Further research is warranted to explore the underlying mechanisms and evaluate the translational potential of LAIBA supplementation in TRS.